<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17203" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Adenosine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Shashank</given-names>
          </name>
          <aff>Louisiana State Un Health Science Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McKintosh</surname>
            <given-names>Rebecca</given-names>
          </name>
          <aff>Tarrant County College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shashank Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebecca McKintosh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17203.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Adenosine has uses as both a diagnostic and therapeutic agent. Adenosine&#x02019;s use as a pharmacological drug works through receptors called purinergic adenosine receptors found throughout the body. As a diagnostic agent, adenosine can be utilized in myocardial perfusion stress imaging due to its vasodilatory effects. As a therapeutic agent, adenosine can be used due to its antiarrhythmic properties in supraventricular tachycardia (SVT). This activity reviews the indications, contraindications, activity, adverse events, and other critical elements of adenosine use and highlights the role of the interprofessional team in managing the care of patients receiving adenosine.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of adenosine, and explain how it works in treating paroxysmal supraventricular tachycardia.</p></list-item><list-item><p>Outline the diagnostic significance of adenosine in cardiac stress testing.</p></list-item><list-item><p>Summarize the most common adverse events associated with adenosine.</p></list-item><list-item><p>Review the importance of coordinating and collaborating among various disciplines in an interprofessional health team to coordinate care and management to enhance outcomes for patients receiving adenosine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17203&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17203">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17203.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Adenosine can serve as a diagnostic or therapeutic agent. Diagnostically, adenosine is one pharmaceutical agent used in a myocardial perfusion stress imaging study for its vasodilatory effects. Therapeutically, adenosine is used for its antiarrhythmic properties in supraventricular tachycardia (SVT) and can function as a diagnostic tool, depending on the type of&#x000a0;SVT.</p>
        <p>Worldwide, glaucoma is the second leading cause of blindness. Endogenous adenosine appears to play a role in the pathophysiology of glaucoma. The experimental adenosine A1 receptor agonist, trabodenoson<xref ref-type="bibr" rid="article-17203.r1">[1]</xref>, is proposed to increase aqueous humor outflow by stimulating trabecular meshwork cells&#x02019; production of matrix metalloproteinases which clears accumulated debris from the eye. However, trabodenoson was not found to be effective in a phase III clinical trial.</p>
        <p>The European Society of Cardiology guidelines advocates using vagal maneuvers and adenosine as first-line therapies in diagnosing and treating supraventricular tachycardia.<xref ref-type="bibr" rid="article-17203.r2">[2]</xref> Second-line treatments include beta-blockers and calcium channel blockers.</p>
        <p>Pediatric supraventricular tachycardia is a common arrhythmia with great clinical significance. If not promptly treated, it can cause cardiogenic shock and heart failure. An infant presented with unstable supraventricular tachycardia.<xref ref-type="bibr" rid="article-17203.r3">[3]</xref> The clinicians tried electrical cardioversion, but the supraventricular tachycardia was resistant. The infant returned to sinus rhythm with a higher dose of adenosine. The clinicians concluded that higher doses of adenosine might be necessary for refractory supraventricular tachycardia.</p>
        <p>The 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care (pediatric life support) gives adenosine a class I recommendation for hemodynamically stable supraventricular tachycardia.<xref ref-type="bibr" rid="article-17203.r4">[4]</xref> Pediatric supraventricular tachycardia is often dependent on the atrioventricular node for its propagation. Adenosine primarily affects the atrioventricular node to stop the arrhythmia. Adenosine failure can occur for two main reasons in treating supraventricular tachycardia: 1) It has a very short half-life, and 2) A non- atrioventricular node-dependent supraventricular tachycardia. Continuous electrocardiogram recordings during adenosine administration can aid clinicians in differentiating between true adenosine resistance (non- atrioventricular node) and transient adenosine effect (short half-life).</p>
        <p>Adenosine triphosphate is metabolized into adenosine when given intravenously was used to treat arrhythmias, and it has similar clinical efficacy to intravenous adenosine. However, adenosine is more stable at room temperature than adenosine triphosphate.<xref ref-type="bibr" rid="article-17203.r5">[5]</xref> Adenosine stops atrioventricular nodal arrhythmias, e.g., atrioventricular reentrant tachycardia and atrioventricular nodal reentrant tachycardia. Adenosine also stops triggered ventricular arrhythmias and many focal atrial tachycardias. Adenosine can be useful in treating wide QRS tachycardia that is hemodynamically stable when it is difficult to differentiate between supraventricular tachycardia and ventricular tachycardia. Adenosine can be used diagnostically for patients with narrow QRS complex tachycardia. Before and after ablation procedures, adenosine can be used to determine accessory pathway conduction which can also be helpful in pulmonary vein isolation. Lastly, neurohumoral syncope is believed to be caused by low plasma concentrations of endogenous adenosine that differ from classical vasovagal syncope.</p>
      </sec>
      <sec id="article-17203.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Adenosine is a purine nucleoside base, most commonly recognized with the molecule adenosine triphosphate, or ATP, and is used thoroughly throughout the entire body in general metabolism.<xref ref-type="bibr" rid="article-17203.r6">[6]</xref>&#x000a0;Adenosine&#x02019;s use as a pharmacological drug works through receptors called purinergic adenosine receptors found throughout the body. Samsel et al. describe four types of adenosine receptors: A1, A2a, A2B, and A3, affecting the immune, nervous, circulatory, respiratory, and urinary systems. Most notably, receptors found in the cardiac atrioventricular (AV) nodal tissue and within the peripheral vasculature exhibit clinical manifestations when administering adenosine.<xref ref-type="bibr" rid="article-17203.r7">[7]</xref><xref ref-type="bibr" rid="article-17203.r8">[8]</xref></p>
        <p>Adenosine further classifies as a miscellaneous antiarrhythmic drug outside the Vaughan-Williams classification scheme. It acts on receptors in the cardiac AV node, significantly slowing conduction time.<xref ref-type="bibr" rid="article-17203.r8">[8]</xref>&#x000a0;This effect occurs by activation of specific potassium channels, driving potassium outside of cells, and inhibition of calcium influx, disrupting the resting potential of the slow nodal cardiac myocyte. Driving potassium outside of the cell causes hyperpolarization of the resting membrane potential while slowing calcium influx causes suppression of calcium-dependent action potentials, all requiring a longer time for depolarization to occur and thus slowing down conduction within these cells, which is useful in supraventricular tachycardia (SVT). SVT is defined as any arrhythmia originating above and including the bundle of His and specifically excludes atrial fibrillation by the ACC/AHA 2015 guidelines.<xref ref-type="bibr" rid="article-17203.r9">[9]</xref></p>
        <p>Usually narrow complex, SVT consists of several specific arrhythmias, which are difficult to diagnose at a high rate (greater than 150 beats per minute). Adenosine has a role in slowing down the heart rate enough to assist in diagnosis. It can also terminate specific reentrant tachycardia involving the AV node, including AV nodal reentrant tachycardia (AVNRT), orthodromic AV reentrant tachycardia (AVRT), and antidromic AVRT. However, extreme caution is necessary when administering adenosine for antidromic AVRT as it should be used only if the diagnosis is certain.</p>
        <p>The objective of a cardiac stress test is to evaluate the patient for significant, stable coronary artery disease and/or prognosis through the induction of ischemia. Adenosine&#x02019;s role in the cardiac stress test is a pharmacologic component of stressing the heart through vasodilation, causing ischemia through a mechanism called a coronary steal.<xref ref-type="bibr" rid="article-17203.r10">[10]</xref>&#x000a0;Adenosine, with the use of a radiotracer for imaging, composes a nuclear cardiac stress test. The use of adenosine in cardiac testing is favorable for evaluating patients with a baseline left bundle branch block morphology on the electrocardiogram. Its limitations, however, are that it can not assess prognosis through functional status as there is no exercise component to the cardiac stress test with adenosine.</p>
        <p>
<bold>Drug Metabolism</bold>
</p>
        <p>Adenosine has a rapid onset of action with a very&#x000a0;short half-life and undergoes rapid intracellular metabolism, either by phosphorylation, forming adenosine monophosphate, or deamination. Phosphorylation via adenosine kinase allows adenosine to be further metabolized as cellular energy, while deamination occurs by adenosine deaminase, eventually forming xanthine and further metabolizing into uric acid.</p>
        <p>Adenosine and its chemical analogs have potential anticancer properties.<xref ref-type="bibr" rid="article-17203.r11">[11]</xref> Tumors possess properties of immune evasion or suppression. Adrenosinergic signaling in the tumor microenvironment is one mechanism of immunosuppression.<xref ref-type="bibr" rid="article-17203.r12">[12]</xref> Adenosine receptor antagonists might have anti-tumor properties.</p>
        <p>Epilepsy affects about 70 million patients worldwide. Endogenous adenosine is thought to play a role in the pathophysiology of epilepsy or seizures.<xref ref-type="bibr" rid="article-17203.r13">[13]</xref> Increased activity of adenosine kinase can reduce adenosine concentration in the CNS leading to more seizure activity. Therefore, medications that increase adenosine&#x02019;s CNS concentrations could be effective antiseizure drugs for treating epilepsy.</p>
        <p>Adenosine receptors have a role in glucose and lipid metabolism. Adenosine receptor agonists and antagonists can affect the balance between glucose and lipid metabolism<xref ref-type="bibr" rid="article-17203.r14">[14]</xref> and thus could be used in future treatments of diabetes mellitus.</p>
        <p>Researchers conducted a small clinical trial on eleven (nine men and two women) conscious subjects.<xref ref-type="bibr" rid="article-17203.r15">[15]</xref> The subjects received randomized doses of adenosine (4 to 512 micrograms) or placebo via a diagnostic catheter located in the carotid artery. Adenosine increased minute ventilation, systolic blood pressure, mean blood pressure, and decreased heart rate. Researchers conclude that adenosine has an excitatory role in carotid bodies, which can help further study carotid body activity in humans.</p>
      </sec>
      <sec id="article-17203.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Adenosine is administered intravenously in specific clinical cases. To manage supraventricular tachycardia (SVT), adenosine is ideally given through a peripheral intravenous (IV) access as a 6 mg dose followed by a 20 mL saline flush for rapid infusion. Subsequent doses start at 12 mg, followed by 20 mL of saline for rapid infusion.<xref ref-type="bibr" rid="article-17203.r16">[16]</xref> The initial dose of adenosine is reduced to a 3 mg bolus if given through an intravenous line that accesses the central circulation, those on dipyridamole or carbamazepine, or if the patient is a cardiac transplant recipient.</p>
        <p>Administration for pharmacological cardiac stress testing is intravenously&#x000a0;as well; however, in a continuous fashion rather than bolus therapy as with SVT. The dose of adenosine used in cardiac stress testing is weight-based and usually administered as 140 mcg/kg per minute.<xref ref-type="bibr" rid="article-17203.r16">[16]</xref></p>
      </sec>
      <sec id="article-17203.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of adenosine are secondary to the activation of adenosine receptors found on vascular tissue, causing vasodilation. Symptoms of skin flushing, lightheadedness, nausea, sweating, nervousness, numbness, and feeling of impending doom have all been described; however, these effects are very&#x000a0;transient and short-lived secondary to adenosine&#x02019;s short half-life.<xref ref-type="bibr" rid="article-17203.r16">[16]</xref></p>
        <p>More severe symptoms are cardiac-related and include the development of cardiac arrhythmia, including premature atrial contractions and premature ventricular contractions, development of AV block, cardiac ischemia, hypotension, and prolonged asystole. Before any administration, the clinician should communicate information to the patient regarding these possible effects. A 68-year-old man with possible coronary artery stenosis was undergoing fractional flow reserve measurement using adenosine administered via intracoronary injection, which immediately caused atrial fibrillation.<xref ref-type="bibr" rid="article-17203.r17">[17]</xref> The patient required drug-induced cardioversion for treatment. The patient had no history of arrhythmias.</p>
        <p>Although presenting a lesser adverse effect, it is essential to&#x000a0;review specific drug-drug interactions involving&#x000a0;adenosine. The effects of adenosine can be blocked by caffeine and theophylline, which fall under a class of drugs called methylxanthines. Methylxanthines derive from another purine base, xanthine, which has a chemical structure sufficiently similar to that of adenine, that they can bind to adenosine receptors acting as a competitive antagonist to adenosine. Patients on these drugs may require larger doses.<xref ref-type="bibr" rid="article-17203.r18">[18]</xref></p>
        <p>Other drug-drug interactions to consider when administering adenosine is the simultaneous use of carbamazepine and dipyridamole. Both these drugs may enhance the adverse effects of adenosine; the clinician should use a decreased initial dose.&#x000a0;</p>
      </sec>
      <sec id="article-17203.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Absolute contraindications include known hypersensitivity to adenosine, heart block, or clinical active bronchospasm, either secondary to reactive airway disease, chronic obstructive pulmonary disease (COPD), or asthma.<xref ref-type="bibr" rid="article-17203.r19">[19]</xref></p>
        <p>Extreme caution is necessary with adenosine administration in any patient with supraventricular tachycardia (SVT) involving an accessory pathway, including Wolf-Parkinson-White (WPW) syndrome. In general, the clinician should not use adenosine in irregular or polymorphic wide-complex tachycardias, a class III recommendation, as the administration can cause degeneration into ventricular fibrillation. Even in the setting of known antidromic AVRT, because of underlying atrial fibrillation, blocking the AV nodal tissue can cause unhindered conduction from the atria to the ventricle through this accessory pathway. While adenosine can slow conduction through the AV node, it does not affect accessory pathways. In such cases, this can cause severe tachycardia that can deteriorate to a non-perfusing rhythm, leading to cardiac arrest.</p>
        <p>Of note, pregnancy is not a deterrent for adenosine administration.<xref ref-type="bibr" rid="article-17203.r20">[20]</xref></p>
      </sec>
      <sec id="article-17203.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Due to the rapidly short half-life of adenosine, the toxic effects of adenosine are kept to a minimum, although there have been reports of severe effects involving prolonged asystole, development of heart block, and cardiac ischemia with adenosine. There is no reversal agent; however, unless the patient sustains a permanent injury, these effects are transient, and patients should receive appropriate supportive measures.</p>
      </sec>
      <sec id="article-17203.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare workers, including cardiologists, nurse practitioners, and pharmacists, who plan to use adenosine, should be very&#x000a0;familiar with the indications and contraindications. Any patient receiving adenosine should be on a form of cardiac monitoring. Patients receiving treatment for supraventricular tachycardia (SVT) are often on a 12-lead electrocardiogram rhythm monitoring to assess the underlying rhythm, while adenosine actively affects the AV node. In cases of Wolf-Parkinson-White (WPW) syndrome, a defibrillator should be available in case of rapid decompensation. If one has never used adenosine before, it is important to first speak to a cardiologist.</p>
        <p>It would also benefit the clinician to consult a cardiology board-certified pharmacist to ensure proper dosing for the application at hand. Cardiology specialty-trained nurses can also assist in administering the drug, helping during a pharmacological stress test, or following up when using adenosine therapeutically. Open communication must exist between the clinician, cardiologist, nurses, and pharmacists so that an interprofessional team works on the case and the patient receives the optimal benefit. [Level 5]</p>
      </sec>
      <sec id="article-17203.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17203&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17203">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17203/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17203">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17203.s10">
        <title>References</title>
        <ref id="article-17203.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hallaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mirza-Aghazadeh-Attari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arasteh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghorbani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jadidi-Niaragh</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Adenosine: The common target between cancer immunotherapy and glaucoma in the eye.</article-title>
            <source>Life Sci</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>282</volume>
            <fpage>119796</fpage>
            <pub-id pub-id-type="pmid">34245774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotadia</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Supraventricular tachycardia: An overview of diagnosis and management.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-47</page-range>
            <pub-id pub-id-type="pmid">31941731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dadi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weiser</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>High-dose adenosine for refractory supraventricular tachycardia: a case report and literature review.</article-title>
            <source>Cardiol Young</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>981</fpage>
            <page-range>981-984</page-range>
            <pub-id pub-id-type="pmid">27989257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shortland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saravu Vijayashankar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sanatani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>When Adenosine Does Not Work: Apparent and Real Adenosine-Resistant Tachycardia.</article-title>
            <source>Pediatr Emerg Care</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>235</fpage>
            <page-range>235-240</page-range>
            <pub-id pub-id-type="pmid">35482497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lokhandwala</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Malviya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Adenosine-A drug with myriad utility in the diagnosis and treatment of arrhythmias.</article-title>
            <source>J Arrhythm</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-112</page-range>
            <pub-id pub-id-type="pmid">33664892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samsel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dzierzbicka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trzonkowski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Adenosine, its analogues and conjugates].</article-title>
            <source>Postepy Hig Med Dosw (Online)</source>
            <year>2013</year>
            <month>Dec</month>
            <day>03</day>
            <volume>67</volume>
            <fpage>1189</fpage>
            <page-range>1189-203</page-range>
            <pub-id pub-id-type="pmid">24379260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mosqueda-Garcia</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Adenosine as a therapeutic agent.</article-title>
            <source>Clin Invest Med</source>
            <year>1992</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>445</fpage>
            <page-range>445-55</page-range>
            <pub-id pub-id-type="pmid">1458718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rankin</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruskin</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>McGovern</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Adenosine and the treatment of supraventricular tachycardia.</article-title>
            <source>Am J Med</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>92</volume>
            <issue>6</issue>
            <fpage>655</fpage>
            <page-range>655-64</page-range>
            <pub-id pub-id-type="pmid">1605147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>NAM</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Indik</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Olshansky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Apr</month>
            <day>05</day>
            <volume>67</volume>
            <issue>13</issue>
            <fpage>e27</fpage>
            <page-range>e27-e115</page-range>
            <pub-id pub-id-type="pmid">26409259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henzlova</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Duvall</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Einstein</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Travin</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Verberne</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers.</article-title>
            <source>J Nucl Cardiol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>606</fpage>
            <page-range>606-39</page-range>
            <pub-id pub-id-type="pmid">26914678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Man</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Potential and promising anticancer drugs from adenosine and its analogs.</article-title>
            <source>Drug Discov Today</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>1490</fpage>
            <page-range>1490-1500</page-range>
            <pub-id pub-id-type="pmid">33639248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.</article-title>
            <source>Annu Rev Med</source>
            <year>2021</year>
            <month>Jan</month>
            <day>27</day>
            <volume>72</volume>
            <fpage>331</fpage>
            <page-range>331-348</page-range>
            <pub-id pub-id-type="pmid">32903139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Adenosine Dysfunction in Epilepsy and Associated Comorbidities.</article-title>
            <source>Curr Drug Targets</source>
            <year>2022</year>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>344</fpage>
            <page-range>344-357</page-range>
            <pub-id pub-id-type="pmid">34602036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanni</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Terre'Blanche</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes.</article-title>
            <source>Rev Endocr Metab Disord</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>1073</fpage>
            <page-range>1073-1090</page-range>
            <pub-id pub-id-type="pmid">34165671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tubek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niewinski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reczuch</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Janczak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rucinski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paleczny</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Engelman</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Banasiak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Paton</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effects of selective carotid body stimulation with adenosine in conscious humans.</article-title>
            <source>J Physiol</source>
            <year>2016</year>
            <month>Nov</month>
            <day>01</day>
            <volume>594</volume>
            <issue>21</issue>
            <fpage>6225</fpage>
            <page-range>6225-6240</page-range>
            <pub-id pub-id-type="pmid">27435894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verani</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological stress with adenosine for myocardial perfusion imaging.</article-title>
            <source>Semin Nucl Med</source>
            <year>1991</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>266</fpage>
            <page-range>266-72</page-range>
            <pub-id pub-id-type="pmid">1948115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rekik</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Intracoronary adenosine induced-atrial fibrillation during fractional flow reserve evaluation].</article-title>
            <source>Ann Cardiol Angeiol (Paris)</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>371</fpage>
            <page-range>371-374</page-range>
            <pub-id pub-id-type="pmid">31471041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riksen</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Smits</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rongen</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>The cardiovascular effects of methylxanthines.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2011</year>
            <issue>200</issue>
            <fpage>413</fpage>
            <page-range>413-37</page-range>
            <pub-id pub-id-type="pmid">20859806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumar</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kronick</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Shuster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Callaway</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kudenchuk</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>McNally</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Silvers</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Passman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sinz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</article-title>
            <source>Circulation</source>
            <year>2010</year>
            <month>Nov</month>
            <day>02</day>
            <volume>122</volume>
            <issue>18 Suppl 3</issue>
            <fpage>S729</fpage>
            <page-range>S729-67</page-range>
            <pub-id pub-id-type="pmid">20956224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17203.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gowda</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Vasavada</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Sacchi</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations.</article-title>
            <source>Int J Cardiol</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>88</volume>
            <issue>2-3</issue>
            <fpage>129</fpage>
            <page-range>129-33</page-range>
            <pub-id pub-id-type="pmid">12714190</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
